Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

被引:389
作者
Hsieh, Andrew C. [1 ,2 ,3 ]
Costa, Maria [1 ,2 ]
Zollo, Ornella [1 ,2 ]
Davis, Cole [1 ,2 ]
Feldman, Morris E. [4 ]
Testa, Joseph R. [5 ]
Meyuhas, Oded [6 ]
Shokat, Kevan M. [4 ]
Ruggero, Davide [1 ,2 ]
机构
[1] Univ Calif San Francisco, Sch Med, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94158 USA
[4] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA
[5] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA
[6] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, IL-91120 Jerusalem, Israel
基金
美国国家卫生研究院;
关键词
T-CELL DEVELOPMENT; MESSENGER-RNA TRANSLATION; RPS6; PHOSPHORYLATION; SIGNALING PATHWAY; PHAS-I; AKT; RAPAMYCIN; SURVIVAL; INITIATION; MINUTE;
D O I
10.1016/j.ccr.2010.01.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We genetically dissect the contribution of the most prominent downstream translational components of mTOR signaling toward Akt-driven lymphomagenesis. While phosphorylation of rpS6 is dispensable for cancer formation, 4EBP-eIF4E exerts significant control over cap-dependent translation, cell growth, cancer initiation, and progression. This effect is mediated at least in part through 4EBP-dependent control of Mcl-1 expression, a key antiapoptotic protein. By using an active site inhibitor of mTOR, PP242, we show a marked therapeutic response in rapamycin-resistant tumors. The therapeutic benefit of PP242 is mediated through inhibition of mTORC1-dependent 4EBP-eIF4E hyperactivation. Thus, the 4EBP-eIF4E axis downstream of mTOR is a druggable mediator of translational control and Akt-mediated tumorigenesis that has important implications for the treatment of human cancers.
引用
收藏
页码:249 / 261
页数:13
相关论文
共 51 条
[51]   Innovation -: T-cell development made simple [J].
Zúñiga-Pflücker, JC .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (01) :67-72